Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's Under Fasting Conditions
Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's Under Fasting Conditions
The purpose of this study is to assess the bioequivalence between Divalproex Sodium ER
 Tablets 500 mg of Dr. Reddy's and Depakote ER 500 mg Tablets of Abbott Laboratories in
 healthy, adult, human subjects, under fasting conditions and to monitor adverse events and
 ensure the safety of subjects.
Open label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose,
 crossover oral bioequivalence study of Divalproex Sodium Extended Release Tablets 500 mg of
 Dr. Reddy's Laboratories Limited, and Depakote ER 500 mg mg Tablets of Abbott Laboratories in
 healthy, adult, human subjects, under fasting conditions.
Inclusion Criteria:

 The subjects were selected for study participation, if they met the following criteria:

 1. Subjects aged between 18 and 45 years (both inclusive).

 2. Subjects' weight within normal range according to normal values for Body Mass Index
 (18.5 to 24.9 kg/m2) with minimum of 50 kg weight.

 3. Subjects with normal health as determined by personal medical history, clinical
 examination and laboratory examinations within the clinically acceptable reference
 range.

 4. Subjects having normal 12-lead electrocardiogram (ECG).

 5. Subjects having normal chest X-Ray (P/A view) whose X-Ray was taken not more than 6
 months prior to the dosing of Period 01.

 6. Subjects having negative urine screen for drugs of abuse (including amphetamines,
 barbiturates, benzodiazepines, marijuana, cocaine, and morphine).

 7. Subjects having negative alcohol breath test.

 8. Subjects willing to adhere to the protocol requirements and to provide written
 informed consent.

 Exclusion Criteria:

 The subjects were excluded from the study, if they met any of the following criteria:

 1. Hypersensitivity to Divalproex or related class of drugs.

 2. History or presence of significant cardiovascular, pulmonary, hepatic, renal,
 gastrointestinal, endocrine, immunological, dermatological, neurological or
 psychiatric disease or disorder.

 3. Any treatment which could bring about induction or inhibition of hepatic microsomal
 enzyme system within 1 month of the study starting.

 4. History or presence of significant alcoholism or drug abuse.

 5. History or presence of significant smoking (more than 10 cigarettes or beedi's/day).

 6. History or presence of asthma, urticaria or other significant allergic reactions.

 7. History or presence of significant gastric and/or duodenal ulceration.

 8. History or presence of significant thyroid disease, adrenal dysfunction, organic
 intracranial lesion such as pituitary tumor.

 9. History or presence of cancer.

 10. Difficulty with donating blood.

 11. Difficulty in swallowing solids like tablets or capsules.

 12. Use of any prescribed or OTC medication during last two weeks prior to dosing in
 period 01.

 13. Major illness during 3 months before screening.

 14. Participation in a drug research study within past 3 months.

 15. Donation of blood in the past 3 months before screening.

 16. Consumption of grapefruit juice, xanthine-containing products, tobacco containing
 products or alcohol for within 48 hours prior to dosing.

 17. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.

 18. History or presence of significant easy bruising or bleeding.

 19. History or presence of significant recent trauma.